CDK4/6 inhibition in cancer: the cell cycle splicing connection.
Journal: 2019/November - Molecular and Cellular Oncology
ISSN: 2372-3556
Abstract:
Cyclin-dependent kinase -4 and -6 (CDK4/6) inhibitors are currently being assessed in clinical trials for the treatment of many cancers including melanoma. While investigating the mechanisms of CDK4/6 inhibitor resistance in melanoma, we uncovered a mechanism of action of these inhibitors in regulating the expression of both the mouse double minute 4 (MDM4) oncogene and tumor protein p53 (TP53).
Relations:
Citations
(1)
Diseases
(1)
Genes
(5)
Processes
(1)
Similar articles
Articles by the same authors
Discussion board
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.